The United States Patent and Trademark Office (USPTO) has issued US patent No. 8,450,300 with claims directed to the Cempra's novel loading dose regimen for Taksta.  The patent, entitled "Fusidic Acid Dosing Regimens for Treatment of Bacterial Infections," provides protection until 2029, excluding possible patent term extensions.

"The issuance of this patent may add to the commercial value of Taksta as an important antibiotic candidate, currently in a phase 2 clinical study in patients with prosthetic joint infections," said Prabhavathi Fernandes, chief executive officer of Cempra.  "Our now proprietary loading dose regimen for Taksta was a novel innovation designed so that the drug would rapidly reach therapeutic blood levels and minimize the risk of drug resistance. The patent provides protection in addition to the expected US market exclusivity obtained through Waxman-Hatch, the GAIN Act, paediatric testing and, possibly, the Orphan Drug Act."

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases.